Peptide-dependent mobilization of CD8 regulatory cells in cardiac transplantation
心脏移植中 CD8 调节细胞的肽依赖性动员
基本信息
- 批准号:10585628
- 负责人:
- 金额:$ 68.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-21 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAlloantigenAllograftingAntibodiesAntibody FormationAntigensB-LymphocytesC-Type LectinsCD4 Positive T LymphocytesCD8 receptorCD8-Positive T-LymphocytesCD8B1 geneCellsChronicClinical DataComplexDataEngineeringGenerationsGenesGeneticGenetic PolymorphismGraft RejectionGraft SurvivalHeartHeart TransplantationHelper-Inducer T-LymphocyteHomologous TransplantationHumanImmune responseInfectionInjuryIsoantibodiesKidneyKidney TransplantationKnockout MiceLibrariesLymphocytic choriomeningitis virusMajor Histocompatibility ComplexMediatingMembrane GlycoproteinsModelingMusMutagenesisMutationNK cell receptor NKB1Natural Killer CellsOrgan TransplantationOutcomePathogenicityPeptide HydrolasesPeptide LibraryPeptidesPositioning AttributeProductionProteinsPublishingQa-1 AntigenReactionRegulationRegulatory T-LymphocyteResearchRoleSignal TransductionSolidSpecificityStressStudy modelsSurfaceT cell responseT-Cell ActivationT-LymphocyteTestingTissue GraftsTissuesVariantYeastsclinical applicationcohortcombinatorialdonor-specific antibodyheart allograftimprovedinsightisoimmunitymouse modelnovelnovel strategiespathogenreceptorreceptor expressionresponseselective expressionsynthetic peptidetransplant modeltreatment strategyvaccine strategy
项目摘要
Project Summary
Antibody-mediated graft rejection (AMR) remains a major barrier to successful solid organ transplantation.
Establishing novel treatment strategies based on our understanding of underlying mechanisms may improve
long term graft outcomes. Although pathogenic allo-antibodies mediating AMR are produced mainly by GC B
cells after induction by follicular T helper (Tfh) cells, regulation of this response is poorly understood. Insight into
mechanisms that regulate these GC responses and dampen AMR to improve heart allograft outcomes are
needed.
We have uncovered and exploited a central role for Qa-1-/HLA-E-restricted CD8 regulatory T cells in the control
of Tfh-dependent DSA responses against donor allografts. Our published and preliminary experimental data
indicate that CD8 Treg that are restricted by class Ib MHC (murine Qa-1/human HLA-E) can be mobilized by
synthetic FL9 peptides to inhibit alloimmune Tfh cells, dampen Ab-mediated injury and prolong heart allograft
survival in fully mismatched heart transplant models. These findings open the possibility of HLA-E-targeted
vaccine strategies that exploit the limited polymorphism of this MHC class Ib gene and avoid problems of class
Ia MHC diversity.
The FL9−Qa-1 complex is upregulated by a subset of activated Tfh cells that drive alloantibody responses.
Identification of synthetic FL9 agonist peptides that mobilize Ag-specific CD8 Treg after a screen of a yeast
peptide library based on the FL9 self-peptide is outlined in SA1. Analysis of mechanisms that underpin peptide-
induced regulation of AMR against heart allografts are addressed in SA2. Targeting of co-receptors that
modulate CD8 Treg activation and function are the subject of SA3. These studies should allow new and effective
approaches to reduce AMR and improve allograft survival.
项目摘要
抗体介导的移植排斥反应(AMR)仍然是实体器官移植成功的主要障碍。
根据我们对潜在机制的理解建立新的治疗策略可能会改善
长期移植结果。虽然介导AMR的致病性同种抗体主要由GC B产生
滤泡性T辅助细胞(Tfh)诱导后,这种反应的调节知之甚少。洞察
调节这些GC反应和抑制AMR以改善心脏移植物结局的机制是
needed.
我们已经发现并利用了Qa-1-/HLA-E-限制性CD 8调节性T细胞在对照组中的核心作用。
对供体同种异体移植物的Tfh依赖性DSA反应。我们发表的和初步的实验数据
表明受Ib类MHC(鼠Qa-1/人HLA-E)限制CD 8 Treg可通过
合成FL 9肽抑制同种免疫Tfh细胞,抑制Ab介导的损伤并延长心脏同种异体移植
在完全不匹配的心脏移植模型中的存活率。这些发现开启了HLA-E靶向治疗的可能性。
利用这种MHC Ib类基因的有限多态性并避免MHC Ib类问题的疫苗策略,
Ia MHC多样性。
FL 9 −Qa-1复合物被激活的Tfh细胞亚群上调,这些细胞驱动同种抗体反应。
在酵母筛选后鉴定动员Ag特异性CD 8 Treg的合成FL 9激动剂肽
基于FL 9自身肽的肽文库概述于SA 1中。分析支持肽-
针对心脏同种异体移植物的AMR的诱导调节在SA 2中论述。靶向共受体,
调节CD 8 Treg的活化和功能是SA 3的主题。这些研究应该允许新的和有效的
减少AMR和提高同种异体移植物存活率的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jamil Azzi其他文献
Jamil Azzi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jamil Azzi', 18)}}的其他基金
The novel role of HLA-E restricted CD8 regulatory T cells in kidney allograft rejection
HLA-E限制性CD8调节性T细胞在肾同种异体移植排斥中的新作用
- 批准号:
10564689 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
The novel role of the immunoproteasome subunit LMP7 in allo-immunity and T cell exhaustion
免疫蛋白酶体亚基 LMP7 在同种免疫和 T 细胞耗竭中的新作用
- 批准号:
10057350 - 财政年份:2017
- 资助金额:
$ 68.01万 - 项目类别:
The novel role of the immunoproteasome subunit LMP7 in allo-immunity and T cell exhaustion
免疫蛋白酶体亚基 LMP7 在同种免疫和 T 细胞耗竭中的新作用
- 批准号:
10302298 - 财政年份:2017
- 资助金额:
$ 68.01万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 68.01万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 68.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 68.01万 - 项目类别: